|
gptkbp:instance_of
|
gptkb:legal_case
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:AMX-0035
|
|
gptkbp:analysis
|
statistical methods
|
|
gptkbp:analyzes
|
gptkb:Dr._John_Doe
|
|
gptkbp:block
|
participant and investigator
|
|
gptkbp:business_model
|
gptkb:board_game
|
|
gptkbp:clinical_trial
|
Phase III
NC T12345678
WHOICTRP
|
|
gptkbp:collaborations
|
gptkb:battle
research institutions
|
|
gptkbp:collection
|
2020-2023
surveys and medical records
|
|
gptkbp:criteria
|
diagnosed with specific cancer
previous treatment with certain therapies
|
|
gptkbp:duration
|
3 years
|
|
gptkbp:end_date
|
2023-12-31
|
|
gptkbp:established
|
gptkb:battle
|
|
gptkbp:events
|
12 months post-treatment
|
|
gptkbp:focuses_on
|
gptkb:healthcare_organization
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PHOENIX trial
|
|
gptkbp:is_protected_by
|
experimental drug
parallel assignment
|
|
gptkbp:is_studied_in
|
multicenter study
|
|
gptkbp:is_tested_for
|
Phase III
|
|
gptkbp:launch_date
|
2020-01-01
|
|
gptkbp:location
|
multiple sites
|
|
gptkbp:members
|
placebo group
|
|
gptkbp:participants
|
quality of life
adult patients
overall survival
progression-free survival
|
|
gptkbp:provides_information_on
|
available upon request
|
|
gptkbp:publishes
|
gptkb:academic_journal
|
|
gptkbp:receives_funding_from
|
government grant
|
|
gptkbp:recorded_by
|
randomized controlled trial
500 patients
|
|
gptkbp:recruitment
|
ongoing
|
|
gptkbp:regulatory_compliance
|
FDA approved
|
|
gptkbp:research
|
pending publication
|
|
gptkbp:research_focus
|
oncology
|
|
gptkbp:result
|
2024-01-15
interim results
|
|
gptkbp:safety_features
|
independent committee
|
|
gptkbp:safety_record
|
ongoing
|
|
gptkbp:sponsor
|
gptkb:Company
|
|
gptkbp:student_enrollment
|
specific criteria
|
|
gptkbp:treatment
|
experimental and control
|
|
gptkbp:vision
|
double-blind
|
|
gptkbp:year
|
2022-12-31
2023-12-31
|